← All stocks

Scribe Therapeutics, Inc.

SCTX Net buying

CIK 0001853921 #3010 in the set updated 17 Sep 2026

Bought (12 mo)

$71.34M

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

+$71.34M

+$71.34M against sales at will

By person

7 insiders · 9 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Aghazadeh Behzad

Director

$36.26M (3)

—

+$36.26M

3,088,888

$56.37M

+342.8%

GORDON CARL L

Director

$15.00M (1)

—

+$15.00M

1,348,825

$24.62M

—

ORBIMED ADVISORS LLC entity

Director

$15.00M (1)

—

+$15.00M

1,348,825

$24.62M

—

AH Bio Fund II, L.P. entity

10% owner

$5.00M (1)

—

+$5.00M

2,385,075

$43.53M

—

Lucas Svetlana

Chief Business Officer

$45.00K (1)

—

+$45.00K

3,000

$54.75K

—

Parrot David

Chief Financial Officer

$39.99K (2)

—

+$39.99K

1,333

$24.33K

—

Doudna Jennifer A

10% owner

—

603,547

$11.01M

+2.1%

No percentages here. Scribe Therapeutics, Inc. reports its share count only per share class, which the XBRL frames API does not carry.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 13

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 4

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 3,459,553

History held since 27 Jul 2026